完全生物可降解支架置入术及术后18个月随访一例
被引量:2
摘要
2012年12月1日厦门市心脏中心为1例不稳定型心绞痛患者实施了完全生物可降解支架置入术,现将患者的基本情况、手术过程和术后18个月的随访情况报道如下。
出处
《中国介入心脏病学杂志》
2014年第10期673-674,共2页
Chinese Journal of Interventional Cardiology
参考文献9
-
1Nishio S, Kosuga K, Igaki K, et al. Long-Term(>10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents:Igaki-Tamai stents. Circulation, 2012, 125:2343-2353.
-
2Onuma , Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation, 2011, 123:779-797.
-
3Onuma , Serruys PW, Perkins LE, et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation, 2010, 122:2288-2300.
-
4Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus- eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc lnterv, 2013, 6:999-1009.
-
5Abizaid A, Costa JR Jr, Bartorelli AL, et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. Eurolntervention, 2014, [Epub ahead of print].
-
6Rzeszutko L, Depukat R, Dudek D. Biodegradable vascular scaffold ABSORB BVS Tra _ scientific evidence and methods of implantation. Postepy Kardioi Inter, 2013, 9:22-30.
-
7Serruys PW, Onuma Y, Garcia-Garcia HM, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus- eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. Eurolntervention, 2014, 9:1271-1284.
-
8Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de- novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet, 2008, 37l:899-907.
-
9Dudek D, Onuma Y, Ormiston JA, et al. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. Eurolntervention, 2012, 7:1060-1061.
同被引文献25
-
1毕胜,纪树荣,顾越,瓮长水.Fugl-Meyer上肢运动功能评分与上肢运动功能状态评分的响应性研究[J].中国康复医学杂志,2006,21(2):118-120. 被引量:134
-
2高润霖.药物洗脱支架研究现状及进展[J].中国实用内科杂志,2006,26(8):1121-1123. 被引量:19
-
3脑卒中患者临床神经功能缺损程度评分标准(1995)[J].中华神经科杂志,1996,29(6):381-383. 被引量:15752
-
4陈佳慧,沈雳,王齐兵,等.冠状动脉生物可降解支架设计与应用:材料学的进一步革新将带来什么?[J].中国组织工程研究,2014,18(30):4878-4888.
-
5Jaruszewski KM,Curran GL,Swaminathan SK,et al. Multimodal Nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain.Biomaterials. 2014;35(6): 1967-1976.
-
6Cheng T J, Ke DS, Guo HR,et aI.The association between arsenic exposure from drinking water and cerebrovascular disease mortality in Taiwan.Water Res. 2010;44(19): 5770-5776.
-
7Inzitari D,Eliasziw M,Gates P, et aI.The causes and risk of stroke in patients with asympt0matic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators.N Engl J Med.2000; 342(23):1693-700.
-
8Kono K,Shintani A,Tanaka Y, et aI.Delayed in-stent occlusion due to stent-related changes in vascular geometry after cerebral aneurysm treatment.Neurol Med Chit (Tokyo).2013 53(3):182-185.
-
9Hunter TB,Yoshino MT, Dzioba RB,et aI.Medical devices of the head, neck, and spine.Radiographics.2004;24(1):257-285.
-
10Fuchs C,Ladwig E,Zhou J,et al.Argatroban administration reduces leukocyte adhesion and improves capillary perfusion within the intestinal microcirculation in experimental sepsis. Thromb Haemost.2010; 104(5): 1022-1028.
二级引证文献3
-
1于一,赵迎新,史冬梅,刘宇扬,刘晓丽,贾硕,吴思婧,孙岩,周玉杰.生物可吸收支架的最新研究进展[J].中国介入心脏病学杂志,2016,24(9):521-525. 被引量:7
-
2高旸,丁嵩,何奔.生物可吸收支架在经皮冠状动脉介入治疗中的应用现状[J].中国介入心脏病学杂志,2017,25(3):163-165. 被引量:5
-
3林润锋.自拟逐痰祛瘀方对脑血管支架术后再狭窄的预防作用研究[J].中西医结合心脑血管病杂志,2017,15(16):2060-2062. 被引量:1
-
1郑晓新,蒋学俊.完全生物可降解支架与再内皮化策略[J].心血管病学进展,2013,34(1):127-130. 被引量:2
-
2侯东明.生物可降解支架[J].国外医学(心血管疾病分册),1996,23(3):146-147. 被引量:2
-
3李可,卢才义.生物可降解血管内支架:希望和挑战[J].国际心血管病杂志,2009,36(4):193-195. 被引量:5
-
4梁滨,孙伟,朱皓,郑振国,张研,尹达,周旭晨.国产EXCEL^(TM)与Friebird2^(TM)药物洗脱支架在ACS治疗中的应用对比观察[J].山东医药,2015,55(12):47-48. 被引量:3
-
5韩欣宇,杨魏.生物可降解镁合金支架研究现状和进展[J].医学综述,2015,21(6):981-983. 被引量:4
-
6赵玉娟,李为民,周立君,杨树森,刘丕栋,李悦,陈彦东,宋丽云,盛力,付兵.国产替罗非班联合生物可降解支架Excel治疗急性冠脉综合征的安全性和疗效[J].中华急诊医学杂志,2009,18(8):835-840. 被引量:4
-
7马宏宇,金至赓,李屹,刘惠亮.生物可降解冠状动脉支架的研究进展[J].中华灾害救援医学,2017,5(3):172-176. 被引量:4
-
8朱悦琦,程英升,李明华.生物可降解支架在良性管腔狭窄成形术中应用的研究进展[J].介入放射学杂志,2008,17(9):675-680. 被引量:13
-
9张宇(摘).生物可降解支架Excel的试验结果[J].国外药讯,2008(8):11-11.
-
10王梦龙,周丽平,黄兵,江洪.BioMatrix Biolimus A9生物可降解支架治疗冠心病安全性和有效性的Meta分析[J].疑难病杂志,2016,15(9):962-966.